Try a new search

Format these results:

Searched for:

in-biosketch:true

person:scherj01

Total Results:

208


Can we modulate the gut microbiome to enhance DMARD efficacy in rheumatoid arthritis?

Blank, Rebecca B; Nayak, Renuka R; Scher, Jose U
PMID: 39551674
ISSN: 1532-866x
CID: 5757972

Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs

Scher, Jose U; Nayak, Renuka; Clemente, Jose C
The increasing prevalence of autoimmune and immune-mediated diseases (AIMDs) underscores the need to understand environmental factors that contribute to their pathogenesis, with the microbiome emerging as a key player. Despite significant advancements in understanding how the microbiome influences physiological and inflammatory responses, translating these findings into clinical practice remains challenging. This viewpoint reviews the progress and obstacles in microbiome research related to AIMDs, examining molecular techniques that enhance our understanding of microbial contributions to disease. We discuss significant discoveries linking specific taxa and metabolites to diseases such as rheumatoid arthritis, systemic lupus erythematosus and spondyloarthritis, highlighting the role of gut dysbiosis and host-microbiome interactions. Furthermore, we explore the potential of microbiome-based therapeutics, including faecal microbiota transplantation and pharmacomicrobiomics, while addressing the challenges of identifying robust microbial targets. We advocate for integrative, transdisease studies and emphasise the need for diverse cohort research to generalise findings across populations. Understanding the microbiome's role in AIMDs will pave the way for personalised medicine and innovative therapeutic strategies.
PMID: 39419539
ISSN: 1468-2060
CID: 5718772

Clinical validation of digital assessment tools and machine learning models for remote measurement of psoriasis and psoriatic arthritis: a proof-of-concept study

Webster, Dan E; Haberman, Rebecca H; Chada, Lourdes Maria Perez; Tummalacherla, Meghasyam; Tediarjo, Aryton; Yadav, Vijay; Neto, Elias Chaibub; MacDuffie, Woody; DePhillips, Michael; Sieg, Eric; Catron, Sydney; Grant, Carly; Francis, Wynona; Nguyen, Marina; Yussuff, Muibat; Castillo, Rochelle L; Yan, Di; Neimann, Andrea L; Reddy, Soumya M; Ogdie, Alexis; Kolivras, Athanassios; Kellen, Michael R; Mangravite, Lara M; Sieberts, Solveig K; Omberg, Larsson; Merola, Joseph F; Scher, Jose U
OBJECTIVE:Psoricatic disease remains underdiagnosed and undertreated. We developed and validated a suite of novel, smartphone sensor-based assessments that can be self-administered to measure cutaneous and musculoskeletal signs and symptoms of psoriatic disease. METHODS:Participants with psoriasis, psoriatic arthritis, or healthy controls were recruited between June 5, 2019, and November 10, 2021, at two academic medical centers. Concordance and accuracy of digital measures and image-based machine learning models were compared to their analogous clinical measures from trained rheumatologists and dermatologists. RESULTS:assessment categorized physician-assessed upper extremity involvement, considering joint tenderness or enthesitis (AUROC = 0.68 (0.47-0.85)). CONCLUSION/CONCLUSIONS:The Psorcast digital assessments achieved significant clinical validity, although they require further validation in larger cohorts before use in evidence-based medicine or clinical trial settings. The smartphone software and analysis pipelines from the Psorcast suite are open source and freely available.
PMID: 38879192
ISSN: 1499-2752
CID: 5671672

Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation

Subudhi, Ipsita; Konieczny, Piotr; Prystupa, Aleksandr; Castillo, Rochelle L; Sze-Tu, Erica; Xing, Yue; Rosenblum, Daniel; Reznikov, Ilana; Sidhu, Ikjot; Loomis, Cynthia; Lu, Catherine P; Anandasabapathy, Niroshana; Suárez-Fariñas, Mayte; Gudjonsson, Johann E; Tsirigos, Aristotelis; Scher, Jose U; Naik, Shruti
Inflammatory epithelial diseases are spurred by the concomitant dysregulation of immune and epithelial cells. How these two dysregulated cellular compartments simultaneously sustain their heightened metabolic demands is unclear. Single-cell and spatial transcriptomics (ST), along with immunofluorescence, revealed that hypoxia-inducible factor 1α (HIF1α), downstream of IL-17 signaling, drove psoriatic epithelial remodeling. Blocking HIF1α in human psoriatic lesions ex vivo impaired glycolysis and phenocopied anti-IL-17 therapy. In a murine model of skin inflammation, epidermal-specific loss of HIF1α or its target gene, glucose transporter 1, ameliorated epidermal, immune, vascular, and neuronal pathology. Mechanistically, glycolysis autonomously fueled epithelial pathology and enhanced lactate production, which augmented the γδ T17 cell response. RORγt-driven genetic deletion or pharmacological inhibition of either lactate-producing enzymes or lactate transporters attenuated epithelial pathology and IL-17A expression in vivo. Our findings identify a metabolic hierarchy between epithelial and immune compartments and the consequent coordination of metabolic processes that sustain inflammatory disease.
PMID: 38772365
ISSN: 1097-4180
CID: 5654422

Prevention of Psoriatic Arthritis: The Need for Prospective Studies

Wu, Alexander; Scher, Jose U; Ogdie, Alexis; Ritchlin, Christopher; Merola, Joseph F
Psoriatic arthritis (PsA) is a systemic chronic inflammatory disease that develops in up to 30% of patients with psoriasis. Mixed data variably support the potential ability to "prevent" and/or delay PsA through use of systemic therapies in psoriasis patients. Though intriguing, almost all of these studies are retrospective in nature, and hold substantial limitations and potential biases that challenge the ability to meaningfully interpretation their results. Thus, the authors believe prospective observational and interventional studies are crucial to understanding our ability to truly modify the transition from psoriasis to psoriatic arthritis and delay or prevent PsA onset.
PMID: 38796274
ISSN: 1558-0520
CID: 5663192

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

Ogdie, Alexis; Merola, Joseph F; Mease, Philip J; Ritchlin, Christopher T; Scher, Jose U; Lafferty, Kimberly Parnell; Chan, Daphne; Chakravarty, Soumya D; Langholff, Wayne; Wang, Yanli; Choi, Olivia; Krol, Yevgeniy; Gottlieb, Alice B
BACKGROUND:Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy or intolerance), treatments utilizing alternative mechanisms of action are needed. In phase 3 studies, the fully human interleukin (IL)-23p19 subunit-inhibitor, guselkumab, was efficacious in patients with active PsA, including TNFi-IR. Efficacy was generally consistent between TNFi-naïve and TNFi-experienced cohorts; however, in the latter, higher response rates have been observed with the Q4W dosing regimen relative to the Q8W dosing regimen for some endpoints, suggesting the need to evaluate whether more frequent dosing may provide an incremental clinical benefit for TNFi-IR patients. METHODS:The phase 3b SOLSTICE study will assess guselkumab efficacy and safety in TNFi-IR PsA patients. Eligibility criteria include a PsA diagnosis for ≥ 6 months; active disease (≥ 3 swollen, ≥ 3 tender joints, C-reactive protein ≥ 0.3 mg/dL); and inadequate efficacy with, and/or intolerance to, one prior TNFi. Participants will be randomized 1:1:1 to guselkumab Q4W or Q8W or placebo→guselkumab Q4W (at Week 24). The primary endpoint is the proportion of patients achieving ≥ 20% improvement in the American College of Rheumatology criteria (ACR20) at Week 24. Major secondary endpoints include ACR50, ACR70; an Investigator's Global Assessment (IGA) of psoriasis score of 0/1 plus ≥ 2-grade reduction and ≥ 90% improvement in Psoriasis Area and Severity Index (both among patients with ≥ 3% body surface area affected by psoriasis and baseline IGA ≥ 2); minimal/very low disease activity; and changes from baseline in Health Assessment Questionnaire-Disability Index, the 36-item Short-Form Health Survey Physical Component Summary, and Functional Assessment of Chronic Illness Therapy-Fatigue scores. The target sample size (N = 450) is estimated to provide > 90% power in detecting differences between each guselkumab group and the placebo group for the primary endpoint assuming a 2-sided α = 0.05. Cochran-Mantel-Haenszel testing and analyses of covariance will be used to compare efficacy for binary and continuous endpoints, respectively. DISCUSSION/CONCLUSIONS:Findings from the phase 3b SOLSTICE study, the design of which was informed by results from previously conducted phase 3 studies, is expected to provide important efficacy and safety information on guselkumab therapy in TNFi-IR patients with PsA. TRIAL REGISTRATION/BACKGROUND:This trial was registered at ClinicalTrials.gov, NCT04936308, on 23 June 2021.
PMCID:11106968
PMID: 38773563
ISSN: 2520-1026
CID: 5654512

SHORT CHAIN FATTY ACIDS MITIGATE OSTEOCLAST-MEDIATED ARTHRITIC BONE REMODELLING

Yang, Katharine Lu; Mullins, Briana J; Lejeune, Alannah; Ivanova, Ellie; Shin, Jong; Bajwa, Sofia; Possemato, Richard; Cadwell, Ken; Scher, Jose U; Koralov, Sergei B
OBJECTIVE:To study the effects of Short Chain Fatty Acids (SCFAs) on arthritic bone remodeling. METHODS:CD4Cre mice, with SCFA supplemented water. We also performed in vitro osteoclast differentiation assays in the presence of serum-level SCFAs to evaluate the direct impact of these microbial metabolites on maturation and function of osteoclasts. We further characterized the molecular mechanism of SCFAs by transcriptional analysis. RESULTS:CD4Cre mice. Further interrogation revealed that bone marrow derived OCPs from diseased mice expressed a higher level of SCFA receptors than that of control mice and that the progenitor cells in the bone marrow of SCFA-treated mice presented a modified transcriptomic landscape, suggesting a direct impact of SCFAs on bone marrow progenitors in the context of osteoporosis. CONCLUSION/CONCLUSIONS:We demonstrated how gut microbiota-derived SCFAs can regulate distal pathology, i.e., osteoporosis, and identified a potential therapeutic option for restoring bone density in rheumatic disease, further highlighting the critical role of the gut-bone axis in these disorders.
PMID: 37994265
ISSN: 2326-5205
CID: 5608662

Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis [Letter]

Haberman, Rebecca H; Zhou, Ying Yin; Catron, Sydney; Felipe, Adamary; Jano, Kathryn; Reddy, Soumya M; Scher, Jose U
PMCID:10914320
PMID: 38428986
ISSN: 1499-2752
CID: 5722862

Use of the Bath Ankylosing Spondylitis Disease Activity Index in Patients With Psoriatic Arthritis With and Without Axial Disease

Reddy, Soumya M; Xue, Katie; Husni, M Elaine; Scher, Jose U; Stephens-Shields, Alisa J; Goel, Niti; Koplin, Joelle; Craig, Ethan T; Walsh, Jessica A; Ogdie, Alexis
OBJECTIVE:To evaluate whether the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a responsive instrument in psoriatic arthritis (PsA) and whether it differentiates between axial and peripheral disease activity in PsA. METHODS:Individuals with PsA initiating therapy in a longitudinal cohort study based in the United States were included. Axial PsA (axPsA), most often also associated with peripheral disease, was defined as fulfillment of the Assessment of Spondyloarthritis international Society axial spondyloarthritis classification criteria or presence of axial disease imaging features. Baseline BASDAI, individual BASDAI items, patient global assessment, patient pain, and Routine Assessment of Patient Index Data 3, and score changes following therapy initiation were descriptively reported. Standardized response means (SRMs) were calculated as the mean change divided by the SD of the change. RESULTS:The mean (SD) baseline BASDAI score at the time of therapy initiation was 5.0 (2.2) among those with axPsA (n = 40) and 4.8 (2.0) among those with peripheral-only disease (n = 79). There was no significant difference in patient-reported outcome scores between the groups. The mean change for BASDAI was similar among axial vs peripheral disease (-0.75 vs -0.83). SRMs were similar across axial vs peripheral disease for BASDAI (-0.37 vs -0.44) and the individual BASDAI items. CONCLUSION/CONCLUSIONS:BASDAI has reasonable responsiveness in PsA but does not differentiate between axPsA and peripheral PsA. (ClinicalTrials.gov: NCT03378336).
PMID: 38101918
ISSN: 1499-2752
CID: 5770582

Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry

Jin, Joy Q; Cronin, Angel; Roberts-Toler, Carla; Yeroushalmi, Samuel; Hadeler, Edward; Spencer, Riley K; Elhage, Kareem G; Gondo, George; Wallace, Elizabeth B; Reddy, Soumya M; Han, George; Kaffenberger, Jessica; Davis, Mitchell S; Hakimi, Marwa; Scher, Jose U; Armstrong, April W; Bhutani, Tina; McLean, Robert R; Liao, Wilson
BACKGROUND:Psoriasis patients with poor therapeutic response to multiple biologic agents are not well-characterized. OBJECTIVE:To describe the characteristics associated with development of multiple biologic failure (MBF) versus good clinical response (GR) to the first biologic. METHODS:This prospective cohort analysis evaluated patients in the multicenter CorEvitas Psoriasis Registry who initiated their first biologic between 2015 and 2020 and were followed for ≥24 months. Multivariable logistic regression identified sociodemographic, clinical, and patient-reported outcomes that differed between MBF (discontinued ≥2 biologics of different classes, each used for ≥90 days, due to inadequate efficacy) and GR (continued use of first biologic for ≥2 years) patients. RESULTS:One thousand thirty-nine patients were analyzed (490 GR [47.2%], 65 MBF [6.3%]). Female sex, shorter psoriasis duration, earlier year of biologic initiation, prior nonbiologic systemic therapy use, history of hyperlipidemia, and Medicaid insurance were significantly associated with MBF, though the latter 2 variables exhibited wider confidence intervals, indicating a lower level of support. The first-to-second biologic sequence most observed with MBF was Tumor necrosis factor-α inhibitor to IL-17 inhibitor use. LIMITATIONS/CONCLUSIONS:Biologic adherence between visits was not evaluated. CONCLUSION/CONCLUSIONS:Approximately 6% of psoriasis patients met MBF criteria. The results identify characteristics associated with MBF that may distinguish patients warranting more frequent follow-up.
PMID: 37495173
ISSN: 1097-6787
CID: 5618852